The rate of HIV-1 disease progression varies widely between individuals. This has been attributed to a combination of virological and immunological events during acute HIV infection (AHI). However, the exact mechanisms explaining the relationship between HIV-1 diversity, evolutionary dynamics and host immune responses, and their effect on disease pathogenesis remain unclear. We aim to dissect HIV-1 viral diversity, evolutionary dynamics and select parts of the innate immune responses observed during AHI, and elucidate virus-host mechanisms involved in the regulation of HIV-1 disease pathogenesis during the acute and chronic stages of infection. A retrospective longitudinal study design from well-characterized AHI cohorts will be used. Archived samples from about 122 patients with AHI (defined as HIV-1 antibody negative and RNA or p24 antigen positive) from Europe (Sweden \[*n* = 32\]) and Africa (Kenya \[*n* = 32\], Rwanda \[*n* = 14\], Uganda \[*n* = 13\], Zambia \[*n* = 15\], and South Africa \[*n* = 16\]) will be included. Each patient will contribute plasma samples from four serial time points (\<14, 30 \[+/− 15\], 90 \[+/− 30\] and 360 \[+/− 180\] days post estimated date of infection, EDI) collected prior to treatment initiation. HIV-1 env sequences determined by single genome sequencing (SGS), with 20 SGS clones from each time point, will be generated. In addition, a selected panel of innate immune markers will be profiled using the Meso Scale Discovery (MSD) electro-chemiluminescence-based platform and/or ELISAs. A multi-dimensional Bayesian framework of hierarchical phylogenetic models (HPM) will be applied, allowing for both fixed and random effects prior specifications to test for differences associated between and within patient group parameters, and where all measured virus-host parameters will be considered simultaneously. In addition, evolutionary parameters in different stages of the disease i.e. acute and chronic phases, will also be measured and accounted for in the HPM by addition of the epoch modeling approach to quantify the relationships between viral parameters, innate responses and their effect on disease pathogenesis. The proposed study is likely to constitute one of the largest virus-host dataset of longitudinally collected data of both virus sequences (covering a wide range of HIV-1 subtypes) and innate immune markers to date. The results of the proposed analyses will increase our understanding of HIV-1 pathogenesis and may have implications for therapeutic and prophylactic vaccine design.
